VEGFA and age-related macular degeneration: Between 2020 and 2040, AMD is estimated to affect approximately 200 million people globally and approximately 2.8 million in Europe; two-thirds of this population will have neovascular AMD, requiring multiple anti-VEGF treatments [2,29].